Trials / Unknown
UnknownNCT02317471
Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | autologous gp96 vaccination | Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery. gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion. |
| DRUG | Oxaliplatin+S-1 | Treatment will be start at the 5th week after the surgery. S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles. |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2014-12-16
- Last updated
- 2016-06-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02317471. Inclusion in this directory is not an endorsement.